KTTAW
Pasithea Therapeutics Corp.Company Information
- Company Name
- Pasithea Therapeutics Corp.
- CIK
- CIK0001841330
- Category
- <br>Emerging growth company
- Ticker: Exchange
- KTTAW: Nasdaq, KTTA: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- KTTAW
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-06-17
- Last sale
- 2025-05-12
- Shares purchased (TTM)
- 299,999
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 16,787,049
- Shares outstanding
- 32,100,063
- Ownership
- 52.30%
Earnings Market Reaction
- Filing date
- 2026-08-14
- Price on filing date
- —
- 1-month reaction
- …
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 46 | 50 | 55 | 4 | 7 | 5 | 7 | 9 | 8 | 12 | 16 | 20 | ||||||
| Available For Sale Securities Debt Securities Current | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Restricted Cash Current | 0 | 0 | 0 | 0 | - | - | - | - | - | - | - | - | ||||||
| Prepaid Expense Current | 2 | 2 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | ||||||
| Other Assets Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets Current | 48 | 53 | 56 | 6 | 9 | 6 | 7 | 10 | 9 | 13 | 17 | 21 | ||||||
| Property Plant And Equipment Net | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Right Of Use Asset | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Finite Lived Intangible Assets Net | 3 | 4 | 4 | - | - | - | 7 | - | - | - | - | 8 | ||||||
| Intangible Assets Net Excluding Goodwill | - | - | 3 | 7 | 7 | 7 | 7 | 7 | 8 | 8 | 8 | - | ||||||
| Goodwill | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Assets | 52 | 56 | 60 | 14 | 17 | 15 | 16 | 19 | 18 | 22 | 26 | 31 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable And Accrued Liabilities Current | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 2 | 3 | 2 | ||||||
| Liabilities Current | 2 | 1 | 5 | 1 | 2 | 2 | 1 | 1 | 1 | 2 | 3 | 2 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Operating Lease Liability Current | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Derivative Liabilities Noncurrent | - | - | - | 0 | 0 | 0 | - | - | - | - | - | 0 | ||||||
| Warrants And Rights Outstanding | 0 | 0 | 0 | - | - | - | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Liabilities Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities | 2 | 2 | 5 | 1 | 2 | 2 | 1 | 1 | 1 | 3 | 3 | 2 | ||||||
Stockholders Equity | ||||||||||||||||||
| Operating Lease Liability Noncurrent | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 128 | 128 | 125 | 72 | 72 | 66 | 64 | 64 | 59 | 59 | 59 | 59 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 0 | 0 | 0 | 0 | 0 | - | -0 | -0 | -0 | -0 | -0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -78 | -73 | -70 | -60 | -57 | -53 | -50 | -46 | -43 | -39 | -35 | -30 | ||||||
| Stockholders Equity | 50 | 55 | 55 | 12 | 15 | 13 | 15 | 18 | 16 | 20 | 23 | 28 | ||||||
| Liabilities And Stockholders Equity | 52 | 56 | 60 | 14 | 17 | 15 | 16 | 19 | 18 | 22 | 26 | 31 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.70 | ||||||
| Common Stock Shares Authorized | 500 | 500 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 495 | ||||||
| Common Stock Shares Issued | 33 | 25 | 23 | 7 | 7 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Shares Outstanding | 33 | 25 | 23 | 7 | 7 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialPasithea Therapeutics Corp. (KTTAW) — SEC Financial Statements & Analysis
Pasithea Therapeutics Corp. (KTTAW) is a pharmaceutical preparations company, incorporated in DE. Pasithea Therapeutics Corp. trades on Nasdaq as: KTTAW, KTTA. Pasithea Therapeutics Corp. (KTTAW)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14. Based on that filing, On profitability, Pasithea Therapeutics Corp. posts an operating margin of -6178.91%, a net margin of -6659.90%, a Return on Equity (ROE) of -65.49%, a Return on Assets (ROA) of -61.97%, and a Return on Invested Capital (ROIC) of -398.08%. Per share, it reports EPS of $-0.66, diluted EPS of $-0.66, free cash flow per share of $-0.55, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of 58.22% year-over-year, and EPS growth of -72.19% year-over-year. On the balance sheet, it maintains a current ratio of 26.25x, a quick ratio of 24.91x, working capital of $46.41M, a debt-to-equity ratio of 0.04x, a debt ratio of 0.04, an interest coverage ratio of -143.42x, free cash flow of $-17.78M (TTM), and net debt of $-45.77M. Figures sourced from SEC EDGAR.
- EPS TTM
- $-0.66
- ROE TTM
- -65.49%
- ROA TTM
- -61.97%
- Debt To Equity
- 0.04x
- Free Cash Flow TTM
- $-17.78M
- Net Revenue TTM Growth 1Y
- -100.00%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Pasithea Therapeutics Corp. in?
Pasithea Therapeutics Corp. (KTTAW) operates in the Pharmaceutical Preparations industry.
What exchange does KTTAW trade on?
Pasithea Therapeutics Corp. (KTTAW) trades on the Nasdaq.
Where is Pasithea Therapeutics Corp. incorporated?
Pasithea Therapeutics Corp. is incorporated in DE.
When was Pasithea Therapeutics Corp. (KTTAW)'s most recent SEC filing?
Pasithea Therapeutics Corp. (KTTAW)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14.
What is KTTAW's EPS (earnings per share)?
Pasithea Therapeutics Corp. (KTTAW)'s trailing twelve month EPS is $-0.66 as of 2026-06-30.
What is KTTAW's ROE (return on equity)?
Pasithea Therapeutics Corp. (KTTAW)'s trailing twelve month Return on Equity (ROE) is -65.49% as of 2026-06-30.
What is KTTAW's ROA (return on assets)?
Pasithea Therapeutics Corp. (KTTAW)'s trailing twelve month Return on Assets (ROA) is -61.97% as of 2026-06-30.
What is KTTAW's ROIC (return on invested capital)?
Pasithea Therapeutics Corp. (KTTAW)'s trailing twelve month Return on Invested Capital (ROIC) is -398.08% as of 2026-06-30.